NEW YORK – A. Menarini Diagnostics and Credo Diagnostics Biomedical announced on Thursday an exclusive distribution agreement for Credo's SARS-CoV-2 assay kit and other assays for diagnosing respiratory syncytial virus and Group Strep A.
The tests run on Credo's VitaPCR, a CE-marked point-of-care molecular platform. The firms said that results for the coronavirus test, which use a nasal or oropharyngeal sample, can be achieved in 20 minutes. The test also recently received the CE mark.Â
According to Credo's website, the VitaPCR requires two minutes of hands-on time and does not require extra equipment such as refrigeration.
Financial and other terms of the deal were not disclosed.